NCT06511050View on ClinicalTrials.gov

Lumbrokinase for Adults With Long Covid, Post-treatment Lyme Disease Syndrome, and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

October 9, 2024

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions
Long CovidPost-treatment Lyme Disease SyndromeChronic Fatigue SyndromeMyalgic Encephalomyelitis
Interventions
DIETARY_SUPPLEMENT

Lumbrokinase

Boluoke® brand lumbrokinase capsules will be taken daily for 6 weeks.

Trial Locations (1)

10029

RECRUITING

The Cohen Center for Recovery from Complex Chronic Illnesses (CoRE), New York

Sponsors
All Listed Sponsors
collaborator

Columbia University

OTHER

collaborator

PolyBio Research Foundation

OTHER

lead

Icahn School of Medicine at Mount Sinai

OTHER